Brain Tumours

Targeted therapy

• Bevacizumab

=> probably no need to cross the BBB • EGFR inhibitors (erlotinib, gefitinib…) => only in patients with sensitizing EGFR mutation • ALK inhibitors (crizotinib, ceritinib…) => only in patients with EML4-ALK translocation